Valneva Austria GmbH

Related records

Trials (50)

• A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)
• A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
• A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
• A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children
• Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis
• An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
• An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84
• Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
• Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
• Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51
• Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51
• Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440
• Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43
• COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222
• COVID-19 Paediatric VLA2001-321 Study
• Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects
• Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study
• Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
• Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination
• Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.